stockrowHims & Hers Health, Inc.
HIMS Healthcare Drug Manufacturers Specialty & Generic
Hims & Hers Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 59.0% from fiscal 2024.
- Revenue
- +38.3%
- EPS
- −294.7%
- Free cash flow
- +5.09%
- Total debt
- +40.8%
Quarter to June 2026, against a year earlier
Follow HIMS
Alert me
Hims & Hers Health, Inc. (HIMS) Return on invested capital
Hims & Hers Health, Inc.'s return on invested capital over the twelve months to 30 June 2026 was −11.4%, down 18.4 percentage points from fiscal 2025 (7.05%). Over the past ten years it has ranged from −1,332.7% (fiscal 2019) to 21.9% (fiscal 2024); the current reading is higher than 91% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 7.05% | (14.87) |
| FY2024 | 21.9% | 36.88 |
| FY2023 | −15.0% | 17.54 |
| FY2022 | −32.5% | (32.50) |
| FY2022 | 0.00% | 82.32 |
| FY2021 | −82.3% | (82.32) |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2020 | 0.00% | 1,332.74 |
| FY2019 | −1,332.7% | (1,332.74) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| SUPN Indivior Pharmaceuticals Inc. compare | 283.0% |
| LQDA Liquidia Corporation compare | 121.1% |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 57.7% |
| LNTH Lantheus Holdings, Inc. compare | 14.6% |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | 8.45% |
| RDY Dr. Reddy's Laboratories Ltd compare | 4.77% |
| ALKS Alkermes plc compare | 1.54% |
| AMLX Amylyx Pharmaceuticals, Inc. compare | 0.00% |
| HIMS Hims & Hers Health, Inc. | −11.4% |
| Drug Manufacturers Specialty & Generic industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on HIMS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement